February 24, 2022
UC San Diego Health is the first hospital system in San Diego County to employ high-intensity, focused ultrasound (HIFU) for minimally invasive prostate cancer treatment.
September 21, 2017
Checkpoint inhibitor-based immunotherapy has been shown to be very effective in recurrent and metastatic head and neck cancer but only in a minority of patients. University of California San Diego School of Medicine researchers may have found a way to double down on immunotherapy’s effectiveness.
November 8, 2017
…known to drive many cancers, especially liver cancer. Researchers have long thought that’s because inflammation directly affects cancer cells, stimulating their division and protecting them from cell death. But University of California San Diego School of Medicine researchers have now found that chronic liver inflammation also promotes cancer by suppressing…
December 16, 2019
University of California San Diego School of Medicine and Moores Cancer Center researchers developed a math equation to predict and detect liver cancer and identified when healthy cells become cancerous.
December 23, 2020
UC San Diego and Ludwig Cancer Research scientists describe how a phenomenon known as “chromothripsis” breaks up chromosomes, which then reassemble in ways that ultimately promote cancer cell growth.
August 28, 2015
Four University of California, San Diego School of Medicine researchers have been selected to receive the newly established National Cancer Institute (NCI) Outstanding Investigator Award. The multi-million dollar awards fund new projects that have an unusual potential in cancer research over seven years.
April 9, 2013
As part of a multicenter clinical trial, researchers at University of California, San Diego School of Medicine are evaluating Pexa-Vec (JX-594) to slow the progression of hepatocellular carcinoma (HCC) or liver cancer. Pexa-Vec is a genetically engineered virus that is used in the smallpox vaccine.
March 18, 2015
Researchers at the San Diego Supercomputer Center (SDSC) and the Moores Cancer Center at the University of California, San Diego, have described for the first time the molecular mechanism of cancer development caused by well-known “resistance” mutations in the gene called epidermal growth factor receptor (EGFR).
January 22, 2015
Upending decades-old dogma, a team of scientists at the University of California, San Diego School of Medicine say enzymes long categorized as promoting cancer are, in fact, tumor suppressors and that current clinical efforts to develop inhibitor-based drugs should instead focus on restoring the enzymes’ activities.
May 19, 2016
…p62 in human liver samples are strongly associated with cancer recurrence and reduced patient survival. In mice, they also found that p62 is required for liver cancer to form.
